104 related articles for article (PubMed ID: 27998118)
1. Controlled Hybrid-Assembly of HPV16/18 L1 Bi VLPs in Vitro.
Jin S; Zheng DD; Sun B; Yu X; Zha X; Liu Y; Wu S; Wu Y
ACS Appl Mater Interfaces; 2016 Dec; 8(50):34244-34251. PubMed ID: 27998118
[TBL] [Abstract][Full Text] [Related]
2. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
3. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
4. Study of infectious virus production from HPV18/16 capsid chimeras.
Chen HS; Bromberg-White J; Conway MJ; Alam S; Meyers C
Virology; 2010 Sep; 405(2):289-99. PubMed ID: 20598725
[TBL] [Abstract][Full Text] [Related]
5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
6. A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses.
Jia C; Yang T; Liu Y; Zhu A; Yin F; Wang Y; Xu L; Wang Y; Yan M; Cai Q; Liang X; Ju R; Chen J; Wang L
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35745-35759. PubMed ID: 30360122
[TBL] [Abstract][Full Text] [Related]
7. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.
Chen XS; Casini G; Harrison SC; Garcea RL
J Mol Biol; 2001 Mar; 307(1):173-82. PubMed ID: 11243812
[TBL] [Abstract][Full Text] [Related]
8. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
9. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.
Carter JJ; Wipf GC; Madeleine MM; Schwartz SM; Koutsky LA; Galloway DA
J Virol; 2006 May; 80(10):4664-72. PubMed ID: 16641259
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an RNA aptamer against HPV-16 L1 virus-like particles.
Leija-Montoya AG; Benítez-Hess ML; Toscano-Garibay JD; Alvarez-Salas LM
Nucleic Acid Ther; 2014 Oct; 24(5):344-55. PubMed ID: 25111024
[TBL] [Abstract][Full Text] [Related]
11. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
[TBL] [Abstract][Full Text] [Related]
12. Hybrid Assembly toward Enhanced Thermal Stability of Virus-like Particles and Antibacterial Activity of Polyoxometalates.
Fu DY; Zhang S; Qu Z; Yu X; Wu Y; Wu L
ACS Appl Mater Interfaces; 2018 Feb; 10(7):6137-6145. PubMed ID: 29381053
[TBL] [Abstract][Full Text] [Related]
13. A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging.
Cerqueira C; Pang YY; Day PM; Thompson CD; Buck CB; Lowy DR; Schiller JT
J Virol; 2016 Jan; 90(2):1096-107. PubMed ID: 26559838
[TBL] [Abstract][Full Text] [Related]
14. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
16. Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter.
Mariz FC; Coimbra EC; Jesus AL; Nascimento LM; Torres FA; Freitas AC
Biomed Res Int; 2015; 2015():594120. PubMed ID: 26090426
[TBL] [Abstract][Full Text] [Related]
17. Structure-based engineering of papillomavirus major capsid l1: controlling particle assembly.
Bishop B; Dasgupta J; Chen XS
Virol J; 2007 Jan; 4():3. PubMed ID: 17210082
[TBL] [Abstract][Full Text] [Related]
18. [Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli].
Xie M; Li S; Shen W; Li Z; Zhuang Y; Mo X; Gu Y; Wu T; Zhang J; Xia N
Sheng Wu Gong Cheng Xue Bao; 2009 Jul; 25(7):1082-7. PubMed ID: 19835152
[TBL] [Abstract][Full Text] [Related]
19. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine.
Deschuyteneer M; Elouahabi A; Plainchamp D; Plisnier M; Soete D; Corazza Y; Lockman L; Giannini S; Deschamps M
Hum Vaccin; 2010 May; 6(5):407-19. PubMed ID: 20953154
[TBL] [Abstract][Full Text] [Related]
20. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
